Cargando…

PET/CT-based adaptive radiotherapy of locally advanced non-small cell lung cancer in multicenter yDEGRO ARO 2017-01 cohort study

BACKGROUND: Stage III non-small cell lung cancer (NSCLC) represents a highly heterogeneous disease and treatment burden. Advances in imaging modality show promising results for radiotherapy planning. In this multicentric study, we evaluated the impact of PET/CT-based radiotherapy planning on the pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Mäurer, Matthias, Käsmann, Lukas, Fleischmann, Daniel F., Oertel, Michael, Jazmati, Danny, Medenwald, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827193/
https://www.ncbi.nlm.nih.gov/pubmed/35139856
http://dx.doi.org/10.1186/s13014-022-01997-5
_version_ 1784647577559367680
author Mäurer, Matthias
Käsmann, Lukas
Fleischmann, Daniel F.
Oertel, Michael
Jazmati, Danny
Medenwald, Daniel
author_facet Mäurer, Matthias
Käsmann, Lukas
Fleischmann, Daniel F.
Oertel, Michael
Jazmati, Danny
Medenwald, Daniel
author_sort Mäurer, Matthias
collection PubMed
description BACKGROUND: Stage III non-small cell lung cancer (NSCLC) represents a highly heterogeneous disease and treatment burden. Advances in imaging modality show promising results for radiotherapy planning. In this multicentric study, we evaluated the impact of PET/CT-based radiotherapy planning on the prognosis of patients with stage III NSCLC. METHOD AND PATIENTS: A retrospective observational cohort study (ARO 2017-01/NCT03055715) was conducted by the young DEGRO trial group of the German Society for Radiation Oncology (DEGRO) with the primary objective to assess the effect of tumour volume change during chemoradiotherapy and the secondary objective to assess the effect of treatment planning on survival. Three hundred forty-seven patients with stage III NSCLC treated at 21 university centers between January 2010 and December 2013 were enrolled in this trial. Patients received primary curative chemoradiotherapy with an intended dose of 50 Gy (hypofractionated) or > 60 Gy (normofractionated). To assess the effect of radiotherapy planning modality on overall survival, we used multivariate frailty models. Models were adjusted for gross tumor volume at the initiation of therapy, age, sex, simultaneous chemotherapy, lung comorbidities, RT dose and tumor grade. By considering the random effect, we can account for heterogeneity in survival and considered covariates within the model in relation to the study side. RESULTS: Patients were predominantly male (n = 269, 78.4%) with mainly adenocarcinoma (56.4%) and an average of 67.2 years. Adaptation of radiotherapy with consecutive reduction of irradiation volume showed no significant disadvantage for patient survival (HR = 1.21, 95% CI 0.89–1.64). The use of PET/CT co-registration in radiation planning tended to result in better oncologic outcomes, although no significant association could be shown (HR = 0.8, 95% CI 0.56–1.16). Centers with a consistent planning strategy performed better than those without a preferred planning method (0.62, 95% CI 0.41–0.94). CONCLUSION: A consistent planning strategy has positive effects on overall survival. The use of PET/CT-based adaptive radiotherapy planning shows a similar survival prospect with the prospective of lower treatment volumes. In future research, toxicities need to be analysed in order to assess such reasoning.
format Online
Article
Text
id pubmed-8827193
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88271932022-02-10 PET/CT-based adaptive radiotherapy of locally advanced non-small cell lung cancer in multicenter yDEGRO ARO 2017-01 cohort study Mäurer, Matthias Käsmann, Lukas Fleischmann, Daniel F. Oertel, Michael Jazmati, Danny Medenwald, Daniel Radiat Oncol Short Report BACKGROUND: Stage III non-small cell lung cancer (NSCLC) represents a highly heterogeneous disease and treatment burden. Advances in imaging modality show promising results for radiotherapy planning. In this multicentric study, we evaluated the impact of PET/CT-based radiotherapy planning on the prognosis of patients with stage III NSCLC. METHOD AND PATIENTS: A retrospective observational cohort study (ARO 2017-01/NCT03055715) was conducted by the young DEGRO trial group of the German Society for Radiation Oncology (DEGRO) with the primary objective to assess the effect of tumour volume change during chemoradiotherapy and the secondary objective to assess the effect of treatment planning on survival. Three hundred forty-seven patients with stage III NSCLC treated at 21 university centers between January 2010 and December 2013 were enrolled in this trial. Patients received primary curative chemoradiotherapy with an intended dose of 50 Gy (hypofractionated) or > 60 Gy (normofractionated). To assess the effect of radiotherapy planning modality on overall survival, we used multivariate frailty models. Models were adjusted for gross tumor volume at the initiation of therapy, age, sex, simultaneous chemotherapy, lung comorbidities, RT dose and tumor grade. By considering the random effect, we can account for heterogeneity in survival and considered covariates within the model in relation to the study side. RESULTS: Patients were predominantly male (n = 269, 78.4%) with mainly adenocarcinoma (56.4%) and an average of 67.2 years. Adaptation of radiotherapy with consecutive reduction of irradiation volume showed no significant disadvantage for patient survival (HR = 1.21, 95% CI 0.89–1.64). The use of PET/CT co-registration in radiation planning tended to result in better oncologic outcomes, although no significant association could be shown (HR = 0.8, 95% CI 0.56–1.16). Centers with a consistent planning strategy performed better than those without a preferred planning method (0.62, 95% CI 0.41–0.94). CONCLUSION: A consistent planning strategy has positive effects on overall survival. The use of PET/CT-based adaptive radiotherapy planning shows a similar survival prospect with the prospective of lower treatment volumes. In future research, toxicities need to be analysed in order to assess such reasoning. BioMed Central 2022-02-09 /pmc/articles/PMC8827193/ /pubmed/35139856 http://dx.doi.org/10.1186/s13014-022-01997-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Short Report
Mäurer, Matthias
Käsmann, Lukas
Fleischmann, Daniel F.
Oertel, Michael
Jazmati, Danny
Medenwald, Daniel
PET/CT-based adaptive radiotherapy of locally advanced non-small cell lung cancer in multicenter yDEGRO ARO 2017-01 cohort study
title PET/CT-based adaptive radiotherapy of locally advanced non-small cell lung cancer in multicenter yDEGRO ARO 2017-01 cohort study
title_full PET/CT-based adaptive radiotherapy of locally advanced non-small cell lung cancer in multicenter yDEGRO ARO 2017-01 cohort study
title_fullStr PET/CT-based adaptive radiotherapy of locally advanced non-small cell lung cancer in multicenter yDEGRO ARO 2017-01 cohort study
title_full_unstemmed PET/CT-based adaptive radiotherapy of locally advanced non-small cell lung cancer in multicenter yDEGRO ARO 2017-01 cohort study
title_short PET/CT-based adaptive radiotherapy of locally advanced non-small cell lung cancer in multicenter yDEGRO ARO 2017-01 cohort study
title_sort pet/ct-based adaptive radiotherapy of locally advanced non-small cell lung cancer in multicenter ydegro aro 2017-01 cohort study
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827193/
https://www.ncbi.nlm.nih.gov/pubmed/35139856
http://dx.doi.org/10.1186/s13014-022-01997-5
work_keys_str_mv AT maurermatthias petctbasedadaptiveradiotherapyoflocallyadvancednonsmallcelllungcancerinmulticenterydegroaro201701cohortstudy
AT kasmannlukas petctbasedadaptiveradiotherapyoflocallyadvancednonsmallcelllungcancerinmulticenterydegroaro201701cohortstudy
AT fleischmanndanielf petctbasedadaptiveradiotherapyoflocallyadvancednonsmallcelllungcancerinmulticenterydegroaro201701cohortstudy
AT oertelmichael petctbasedadaptiveradiotherapyoflocallyadvancednonsmallcelllungcancerinmulticenterydegroaro201701cohortstudy
AT jazmatidanny petctbasedadaptiveradiotherapyoflocallyadvancednonsmallcelllungcancerinmulticenterydegroaro201701cohortstudy
AT medenwalddaniel petctbasedadaptiveradiotherapyoflocallyadvancednonsmallcelllungcancerinmulticenterydegroaro201701cohortstudy
AT petctbasedadaptiveradiotherapyoflocallyadvancednonsmallcelllungcancerinmulticenterydegroaro201701cohortstudy